BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18319106)

  • 1. Bevacizumab and macular edema.
    Kumar A
    Ophthalmology; 2008 Mar; 115(3):585. PubMed ID: 18319106
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal bevacizumab for treatment of uveitic macular edema.
    Cordero Coma M; Sobrin L; Onal S; Christen W; Foster CS
    Ophthalmology; 2007 Aug; 114(8):1574-1579.e1. PubMed ID: 17363060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment of article by Matsumoto Y.
    Campa C; D'Angelo S; Incorvaia C
    Retina; 2008 May; 28(5):782; author reply 782-3. PubMed ID: 18463528
    [No Abstract]   [Full Text] [Related]  

  • 4. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
    Querques G
    Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease.
    Mirshahi A; Namavari A; Djalilian A; Moharamzad Y; Chams H
    Ocul Immunol Inflamm; 2009; 17(1):59-64. PubMed ID: 19294576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab.
    Barone A; Prascina F; Russo V; Iaculli C; Primavera V; Querques G; Stella A; Delle Noci N
    J Cataract Refract Surg; 2008 Jul; 34(7):1210-2. PubMed ID: 18571091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis.
    Erdurman FC; Durukan AH; Mumcuoğlu T; Hürmeriç V
    Ocul Immunol Inflamm; 2009; 17(1):56-8. PubMed ID: 19294575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab in postoperative pseudophakic cystoid macular edema: does it really work?
    Spitzer MS; Szurman P; Bartz-Schmidt KU
    J Cataract Refract Surg; 2008 Jun; 34(6):880; author reply 880-1. PubMed ID: 18498977
    [No Abstract]   [Full Text] [Related]  

  • 12. OCT and cataract.
    Falavarjani KG; Modarres M; Nikeghbali A
    Ophthalmology; 2010 Apr; 117(4):849; author reply 849-50. PubMed ID: 20346827
    [No Abstract]   [Full Text] [Related]  

  • 13. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
    Matsumoto Y; Freund KB; Peiretti E; Cooney MJ; Ferrara DC; Yannuzzi LA
    Retina; 2007; 27(4):426-31. PubMed ID: 17420693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
    Barone A; Russo V; Prascina F; Delle Noci N
    Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.
    Mackensen F; Heinz C; Becker MD; Heiligenhaus A
    Retina; 2008 Jan; 28(1):41-5. PubMed ID: 18185136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranibizumab for refractory uveitis-related macular edema.
    Acharya NR; Hong KC; Lee SM
    Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
    Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
    Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.
    Abegg M; Tappeiner C; Wolf-Schnurrbusch U; Barthelmes D; Wolf S; Fleischhauer J
    BMC Ophthalmol; 2008 Sep; 8():18. PubMed ID: 18823536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
    Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
    Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.